Hello! Carvedilol is a beta-blocker (third generation). See the information below for details. 1. Drug name: Carvedilol sustained-release tablets 2. Dosage form: sustained- and controlled-release preparations 3. Registration classification: Class 5 chemical drugs (special dosage forms, new drug certificates can be obtained) 4. Indications: (1) Primary high Blood pressure (2) Cardiac insufficiency, mild or moderate cardiac insufficiency (NYHA class II or III). 5. Specifications: 10mg; 20mg; 40mg; 80mg 6. Usage and dosage: once a day. 7. Project introduction: On October 20, 2006, the US FDA approved SB PHARMCO’s carvedilol controlled-release tablets (COREG CR). This product, taken once a day, can treat three important cardiovascular disease symptoms: hypertension, myocardial infarction, and mild to severe heart failure. This product is divided into an immediate release layer and a sustained release layer, which can maintain the blood concentration in the body for 24 hours, allowing for once-daily administration, which is more convenient than twice-daily administration of carvedilol ordinary tablets, and simplifies the treatment plan. , improved compliance in patients with heart disease. Carvedilol is a third-generation beta-blocker (lowers heart rate and pump force). Studies have shown that Coreg CR is generally well tolerated by patients and has a low incidence of adverse reactions. Once-a-day Coreg CR is approved for the same indications as carvedilol's regular formulation, and is of great significance for the treatment of heart disease. Multiple clinical studies have shown the benefits of carvedilol. More than 3,000 heart failure patients who received carvedilol lived 1.4 years longer than those who took the beta-blocker metoprolol tartrate. 8. Development ideas: We copy the carvedilol sustained-release tablets marketed abroad, which are divided into immediate-release layers and sustained-release layers. After inquiries, we found that some domestic companies have applied for patents on carvedilol control preparations, and the preparation technology we use is not restricted by them. This preparation also does not face administrative protection issues. For reference only.